The effect of oral treatment with the thiazine derivative almitrine bismesylate was studied in 28 patients with chronic obstructive pulmonary disease and arterial hypoxaemia receiving long term domiciliary oxygen therapy in a placebo controlled, double blind crossover trial. The initial treatment was given for three months and the second for two months. Because shown conclusively to improve survivial,34 but it is costly and onerous despite the use of oxygen concentrators.5 During acute exacerbations higher oxygen delivery rates may be needed to achieve an adequate Pao2 but this may cause an acute rise in Paco2, probably resulting from a reduction in hypoxic drive and an aquired insensitivity to carbon dioxide.6
Abstract
The effect of oral treatment with the thiazine derivative almitrine bismesylate was studied in 28 patients with chronic obstructive pulmonary disease and arterial hypoxaemia receiving long term domiciliary oxygen therapy in a placebo controlled, double blind crossover trial. The initial treatment was given for three months and the second for two months. Because almitrine had an unexpectedly prolonged washout effect crossover analysis could not be performed; data from the placebo treatment administered in the second arm of the trial were used to calculate the halflife ofalmitrine. Nine patients were withdrawn from the study (5 almitrine, 4 placebo). Patients' tolerance of the drug was good. The estimated plasma half life of almitrine was 20 5 days, considerably longer than previously reported. Almitrine caused a significant improvement in arterial oxygen tension (Pao2) with a mean maximum increase of 0 7 kPa at a plasma concentration of 500 nglml. Higher plasma concentrations were not associated with any further increase in Pao2. There was no significant effect on arterial carbon dioxide tension (Paco2). In a second, acute study at the end ofeach arm of the chronic trial nine patients were subjected to increasing oxygen delivery rates (2, 4 , and 6 l/min) for 90 minutes or until blood gas concentrations plateaued. Almitrine shown conclusively to improve survivial,34 but it is costly and onerous despite the use of oxygen concentrators.5 During acute exacerbations higher oxygen delivery rates may be needed to achieve an adequate Pao2 but this may cause an acute rise in Paco2, probably resulting from a reduction in hypoxic drive and an aquired insensitivity to carbon dioxide. 6 In theory, respiratory stimulants would be an attractive means of reducing the requirement for oxygen therapy during periods of stability. Such drugs might in addition prevent the rise in Paco2 associated with the use of higher oxygen delivery rates during acute exacerbations. So far, however, respiratory stimulants have provided little convincing therapeutic benefit and many undesirable side effects.7
Almitrine bismesylate, a triazine derivative, is a recently developed oral respiratory stimulant that differs from previous respiratory agonists by acting on peripheral chemoreceptors, principally the carotid body, to increase tidal volume. Oral doses of 50 mg twice daily produce plasma concentrations of 200-400 ng/ml.' Almitrine in clinical trials in patients with chronic obstructive lung disease has been shown to increase Pao2 by 0-5-1 2 kPa and reduce Paco2 by up to 10 kPa.9 0
The aims of this study were therefore twofold: firstly, to evaluate the tolerance and efficacy of almitrine in improving arterial blood gas tensions in patients with hypoxic cor pulmonale already receiving long term domiciliary oxygen therapy; and, secondly, to assess the effects of almitrine on arterial gas tensions in patients with stable hypoxic cor pulmonale breathing oxygen at high delivery rates, to see if the drug would augment the increase in Pao2 while obviating any accompanying rise in Paco2.
Methods

SUBJECTS
Seventeen men and 11 women (mean (SD) age 64-4 (6-2) years) with severe airways obstruction (FEVy 0-62 (0 28) 1, FVC (0-45) 1) were studied in the long term or "chronic" trial. All were hypoxaemic (arterial blood gases breathing air: Pao2 6 2 (0 9) kPa, Paco2 (0-8) kPa) and had had at least one documented episode of peripheral oedema. They were receiving controlled oxygen therapy by nasal cannula at 2 Nine of these patients (Pao2 6-3 (0-7) kPa, Paco2 6-5 (0 06) kPa breathing air) also participated in the second, "acute" study. In both studies the patient's usual medications were continued throughout; these were diuretics ( Patients were visited at home on day 0 (pretreatment) and day 7, and at four week intervals thereafter throughout the trial. Subjects were also visited one to three weeks before entering the trial to check their clinical state and oxygen delivery system. At each visit oxygen therapy was continued from the previous night until after an arterial sample had been taken to ensure that gas tensions were measured during a period of stability. The oxygen delivery system was checked, patients were examined clinically, spirometry was performed, and venous blood samples were obtained for plasma almitrine estimation and routine haematological and biochemical tests. All blood samples were taken two to three hours after the drug was taken, when peak plasma almitrine concentrations would be expected.'2 Acute study
The study was designed as a double blind, placebo controlled trial to be carried out on two study days at the end of each arm of the chronic trial, in which all nine patients also participated. During each study day patients were admitted to the respiratory function unit. An indwelling radial artery cannula was inserted and oxygen, initially at 2 1/min, was administered via nasal cannulae. After a one hour stabilisation period, arterial samples were withdrawn for blood gas estimation at 15 minute intervals and analysed immediately until three consecutive measurements of Pao2 and Paco2 varied by 0 5 kPa or less. The last of these was recorded and a blood sample taken for almitrine estimation. The oxygen delivery rate was then adjusted. This procedure was repeated at flow rates of 4 1/min, 6 1/min, and finally 2 1/min again. Patients continued their routine medications on the day of study, but refrained from taking beverages containing caffeine.
DATA ANALYSIS
Chronic study Plasma almitrine analysis obtained after completion of the study showed that almitrine was detectable in the blood for several weeks after drug administration had been stopped. Thus patients given placebo tablets in the second arm of the trial had appreciable blood concentrations of almitrine for most or all of this time. Conventional analysis, comparing the blood gas results from each arm of the trial, was thus impossible. The blood gas results and plasma almitrine concentrations obtained from each home visit for the 19 patients completing the study were analysed. Arterial blood gas concentrations were related to plasma almitrine concentrations and curves with 95%O confidence limits were fitted to the data by means of the GLIM statistical package and standard curve fitting techniques.3 14 F ratios were generated to test the fit of these curves.
The half life of almitrine was estimated by fitting an exponential function to the plasma almitrine concentrations determined for the 10 patients who completed the second arm of the chronic study taking placebo. Dependence of half life on the initial drug concentration was tested by estimating the rate of elimination separately for each patient, and correlating these rates with the initial drug concentrations by the use of Spearman's rank coefficient. Values of less than 0 05 were considered significant.
Acute study As almitrine had a longer half life than expected, the acute study similarly did not have a crossover design. The relation between arterial gas tensions and almitrine concentrations and oxygen flow rates was obtained by regressing blood gas tensions on the natural logarithms of the blood almitrine measurements, with oxygen flow treated as a factor with three levels. The regression modes included a separate term for the baseline value of each patient. F ratios were generated to test the significance of the estimated effects, which were considered significant at or below the 5 o level. Approximate 9500 confidence intervals for the regression estimates (that is, the predicted mean value) were calculated for a patient with average baseline gas tensions, the GLIM statistical package"' 4 again being used. Half life of almitrine Plasma concentration-time curves for 10 individuals after drug withdrawal and the estimated half life of the drug are shown in figure 1 . Almitrine was detected in the blood of some patients for many days after active drug administration had ceased. The half life of almitrine was calculated as 20-5 days (95% confidence limits 13, 43 days). There was no correlation between half life and initial drug concentration (p > 0 05).
Arterial gas tensions Changes in Pao, and Paco2 during the breathing of domiciliary oxygen in relation to blood almitrine concentrations from the 19 patients completing the trial are shown in figure 2 ; each curve comprises 114 data points. Four values from each curve corresponded to almitrine concentrations above 500 ng/ml and are not shown. There was a curvilinear increase in Pao2 from a baseline concentration of 8-8 (95% confidence limits 8-5, 9-0) kPa to a maximum of 9 5 (9-1, 9-8) kPa at a plasma almitrine concentration of 500 ng/ml, beyond which the effect plateaued. There was a slight but statistically insignificant fall in Paco2 from a baseline concentration of 7A4 (7-2, 7-6) kPa to 7-0 (6-2, 7-8) kPa at an almitrine concentration of 500 ng/ml. 
Discussion
Almitrine was generally well tolerated by our ie stable subjects, whose most frequent complaints were gen flow increased breathlessness, nausea, and nonmin and specific malaise, which occurred equally in the ntrations groups having placebo and active treatment; )atients). only one patient had drug concentrations that )ject, the were unacceptably high. Almitrine has been er a few reported to cause breathlessness in normal or eight subjects'5 and patients with chronic obstructive nt. Data lung disease,'6 17 with an increased incidence at aring the higher drug concentrations; other trials, !fore had however, have reported a reduction in dysro when pnoea scores.9 The other withdrawals in the shown. active treatment group were associated with L blood malaise and gastrointestinal symptoms, as has It each of been reported previously. ' 
hown in
The plasma half life of almitrine in our study of 72 (mean 20-5 days) is more than two weeks longer Llmitrine than that reported after three weeks' oral 'ml. Pao2 administration in healthy subjects," though a kcreasing more prolonged half life has been reported in it higher patients with chronic obstructive lung disease ;e in Pao2 after several months' administration.'0 Delayed ilmitrine clearance of almitrine may occur in patients [average with cirrhosis, but there was no evidence of ilmitrine hepatic dysfunction in any of our patients.
Reasons for the long half life may be straightforward. Studies with radiolabelled drug show ygen flow a very large volume of distribution (15 Almitrine did not modify the rise in Paco2 seen with high oxygen flow rates. This, together with the findings of the chronic study, suggests that at least some of the improvement in Pao2 was brought about by mechanisms other than increased alveolar ventilation, such as improvements in V/Q matching. '6 25 Our study suggests that the increase in Pao2 with almitrine is maintained over three months in patients with hypoxic cor pulmonale receiving long term domiciliary oxygen. There was no accompanying change in arterial Pco2. The long half life of the drug means that dosage schedules may need to be revised. In patients with chronic obstructive lung disease receiving long term oxygen who cannot attain a Pao2 of at least 8 kPa without excessive hypercapnia supplemental almitrine bismesylate may be a useful additional treatment. The acute study confirmed the effects ofalmitrine and oxygen to be additive in increasing Pao2 in patients with chronic obstructive lung disease. The effect of almitrine diminishes as Pao2 approaches normal levels, but again no effect on Paco2 could be found.
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